We appreciate the interest and comments from Rezazadeh et al.1 regarding our article, and we agree on the relevance of electrolyte imbalance in patients with coronavirus 2019 disease (COVID-19), in particular hypokalemia and hypomagnesemia; the reference to hyperkalemia and hypermagnesemia corresponds to a translation error in the document, which has already been corrected. We would like to point out that hypokalemia, as well as hyponatremia and hypocalcemia, appear to be common in patients with severe clinical forms of COVID-19.2–4 Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs thanks to the binding of the virus to angiotensin-converting enzyme 2, reducing the expression of the enzyme with a consequent increase in circulating angiotensin II, which promotes renal potassium loss.2,3,5 In addition, the inflammatory state and gastrointestinal losses can contribute to these imbalances, with potentially significant consequences due to the association with arrhythmic events secondary to QT interval prolongation (especially torsade de pointes), the risk for which increases with the use of certain drugs and also with the inflammatory state itself.1,5,6 The infection may also predispose to myocardial damage, especially in patients with existing cardiovascular disease.2,3 The pathophysiological changes in aging make older patients particularly vulnerable to electrolyte imbalances, so adequate monitoring and early correction are essential.7